Table 1.
Baseline characteristics of patients with osteoporosis who newly initiated teriparatide treatment by post-index fracture status
| Patient characteristics | Fracture patients | Non-fracture patients | p value | Total | |||
|---|---|---|---|---|---|---|---|
| N/mean | Percent/SD | N/mean | Percent/SD | N/mean | Percent/SD | ||
| Total number of patients | 1527 | 13.4 % | 9880 | 86.6 % | 11,407 | 100 % | |
| Age (mean, SD) | 72.4 | 10.5 | 69.1 | 10.5 | <0.001 | 69.5 | 10.6 |
| Age range (N, %) | |||||||
| 50–54 | 88 | 5.8 % | 851 | 8.6 % | <0.001 | 939 | 8.2 % |
| 55–59 | 151 | 9.9 % | 1531 | 15.5 % | <0.001 | 1682 | 14.7 % |
| 60–64 | 158 | 10.3 % | 1393 | 14.1 % | <0.001 | 1551 | 13.6 % |
| 65–69 | 155 | 10.2 % | 1178 | 11.9 % | 0.045 | 1333 | 11.7 % |
| 70–79 | 544 | 35.6 % | 3032 | 30.7 % | <0.001 | 3576 | 31.3 % |
| 80+ | 431 | 28.2 % | 1895 | 19.2 % | <0.001 | 2326 | 20.4 % |
| Female (N, %) | 1412 | 92.5 % | 9084 | 91.9 % | 0.481 | 10,496 | 92.0 % |
| Medicare payer (N, %) | 1146 | 75.0 % | 6167 | 62.4 % | <0.001 | 7313 | 64.1 % |
| Capitated services (N, %) | 38 | 2.5 % | 379 | 3.8 % | 0.009 | 417 | 3.7 % |
| Insurance plan type (N, %) | |||||||
| Comprehensive | 789 | 51.7 % | 4469 | 45.2 % | <0.001 | 5258 | 46.1 % |
| Point of service | 63 | 4.1 % | 621 | 6.3 % | 0.001 | 684 | 6.0 % |
| HMO | 60 | 3.9 % | 623 | 6.3 % | <0.001 | 683 | 6.0 % |
| PPO | 588 | 38.5 % | 3957 | 40.1 % | 0.251 | 4545 | 39.8 % |
| Other/unknown | 27 | 1.8 % | 210 | 2.1 % | 0.362 | 237 | 2.1 % |
| Region (N, %) | |||||||
| Northeast | 124 | 8.1 % | 663 | 6.7 % | 0.043 | 787 | 6.9 % |
| North Central | 581 | 38.0 % | 3505 | 35.5 % | 0.051 | 4086 | 35.8 % |
| South | 590 | 38.6 % | 4354 | 44.1 % | <0.001 | 4944 | 43.3 % |
| West | 229 | 15.0 % | 1322 | 13.4 % | 0.086 | 1551 | 13.6 % |
| Unknown | 3 | 0.2 % | 36 | 0.4 % | 0.296 | 39 | 0.3 % |
| DCI (mean, SD) | 0.97 | 1.23 | 0.63 | 0.99 | <0.001 | 0.68 | 1.03 |
| Unique 3-digit ICD-9 codes (mean, SD) | 14.8 | 8.8 | 11.7 | 7.3 | <0.001 | 12.1 | 7.6 |
| Baseline comorbid conditions (N, %) | |||||||
| Abnormalities of the esophagus | 53 | 3.5 % | 436 | 4.4 % | 0.091 | 489 | 4.3 % |
| Active UGI ulcer | 28 | 1.8 % | 125 | 1.3 % | 0.072 | 153 | 1.3 % |
| Alcoholism | 6 | 0.4 % | 30 | 0.3 % | 0.563 | 36 | 0.3 % |
| Diabetes | 214 | 14.0 % | 915 | 9.3 % | <0.001 | 1129 | 9.9 % |
| Endocrine disease (excluding diabetes) | 69 | 4.5 % | 354 | 3.6 % | 0.072 | 423 | 3.7 % |
| GERD | 180 | 11.8 % | 1111 | 11.2 % | 0.533 | 1291 | 11.3 % |
| Renal insufficiency | 2 | 0.1 % | 61 | 0.6 % | 0.017 | 63 | 0.6 % |
| Liver disease | 26 | 1.7 % | 181 | 1.8 % | 0.725 | 207 | 1.8 % |
| Malabsorption syndrome | 6 | 0.4 % | 59 | 0.6 % | 0.324 | 65 | 0.6 % |
| Metabolic bone disease | 31 | 2.0 % | 257 | 2.6 % | 0.186 | 288 | 2.5 % |
| Nephritis | 12 | 0.8 % | 52 | 0.5 % | 0.206 | 64 | 0.6 % |
| Osteopenia | 137 | 9.0 % | 900 | 9.1 % | 0.862 | 1037 | 9.1 % |
| Rheumatoid arthritis | 185 | 12.1 % | 706 | 7.1 % | <0.001 | 891 | 7.8 % |
| Thyroid disease | 222 | 14.5 % | 1319 | 13.4 % | 0.206 | 1541 | 13.5 % |
| Fragility-related fractures (N, %) | 544 | 35.6 % | 2376 | 24.0 % | <0.001 | 2920 | 25.6 % |
| Vertebral | 207 | 13.6 % | 1326 | 13.4 % | 0.886 | 1533 | 13.4 % |
| Hip | 107 | 7.0 % | 323 | 3.3 % | <0.001 | 430 | 3.8 % |
| Non-hip non-vertebral | 252 | 16.5 % | 793 | 8.0 % | <0.001 | 1045 | 9.2 % |
| Multiple fractures | 22 | 1.4 % | 65 | 0.7 % | 0.001 | 87 | 0.8 % |
| Antiresorptive use (N, %) | 1,003 | 65.7 % | 6302 | 63.8 % | 0.150 | 7305 | 64.0 % |
| Raloxifene use (N, %) | 205 | 13.4 % | 1357 | 13.7 % | 0.743 | 1562 | 13.7 % |
| Antiresorptive agent count (mean, SD) | 1.1 | 0.2 | 1.1 | 0.2 | 0.538 | 1.1 | 0.2 |
| Days on antiresorptives (mean, SD) | 209.7 | 102.3 | 219.0 | 100.9 | 0.001 | 217.7 | 101.1 |
| Antiresorptive MPR (mean, SD) | 0.73 | 0.26 | 0.75 | 0.25 | 0.004 | 0.75 | 0.25 |
The italicized values denote p < 0.001